Skip to main content
Equibles
PROF logo

PROF · Profound Medical Corp. · Metrics

Track PROF — free

Use PROF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PROF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.21 +0.33 (+4.80%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$252.62M
Shares
36.63M
Volume · Nov 6 322.39K Avg daily vol (3M) 204.52K

PROF metrics

85 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$7.21
Market cap
$252.62M

Price action

23 metrics
Price change (1W)
+17.4%
Price change (30D)
+21.1%
Price change (3M)
-13.4%
Price change (6M)
-3.9%
Price change (YTD)
-12.6%
Price change (1Y)
+17.4%
Trailing year
Price change (5Y)
-39.1%
52-week high
$8.65
52-week low
$5.06
Change from 52-week high
-20.5%
Change from 52-week low
+36.0%
Annualized volatility
68.8%
Annualized volatility (3M)
72.1%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.4
RSI (14D)
60.2
Price vs SMA 50
+10.4%
Price vs SMA 200
+3.5%
Avg volume (3M)
200,907
Relative volume
1.1
Average dollar volume
$1.31M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
36.63M

Valuation

12 metrics
P / E (TTM)
4.4
Trailing earnings · reciprocal yield 22.5%
PEG ratio
0.2
EV / revenue
9.5×
reciprocal yield 10.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
10.7×
reciprocal yield 9.4%
P / book
5.9
reciprocal yield 16.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-12.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
11.5×
reciprocal yield 8.7%
EV / revenue historical average (5Y)
11.5×
reciprocal yield 8.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
73.9%
Operating margin
-145.1%
Trailing 12 months
Net margin
-137.5%
Gross profit (TTM)
$17.45M
Operating profit (TTM)
−$34.28M
Net income (TTM)
−$32.49M
Trailing 12 months
Diluted EPS (TTM)
$1.55
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.68
Gross profit per diluted share (TTM)
$0.50
Operating profit per diluted share (TTM)
$-0.98
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.93
Operating cash flow per diluted share (TTM)
$-0.90
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.60
Stock compensation per diluted share (TTM)
$0.10
Book value per share
$1.16

Growth

11 metrics
Revenue growth YoY
+85.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$23.63M
Trailing 12 months
EPS growth YoY
+25.9%
Shares change YoY
+21.4%
Year over year · more shares
Revenue CAGR (3Y)
+34.1%
Revenue CAGR (5Y)
+17.1%
EPS CAGR (3Y)
+0.7%
EPS CAGR (5Y)
+2.4%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-76.4%
Return on assets
-55.9%
Debt / equity
0.1
Current ratio
4.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$28.83M
Latest balance sheet
Cash & equivalents
$33.34M
Total assets
$58.15M
Total debt
$4.51M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$31.49M
Capital expenditures (TTM)
—
R&D (TTM)
$20.99M
SG&A (TTM)
$30.73M
Stock compensation (TTM)
$3.56M
R&D / revenue
88.9%
Stock compensation / revenue
15.1%

Ownership (13F)

9 metrics
13F filers
57
13F filer change QoQ
-1
Institutional ownership
44.2%
Conviction holders (share of 13F filers)
1.8%
Crowding (high-turnover and private-fund holders)
20.4%
Private-fund adviser ownership
14.9%
Active holders' share change QoQ
-0.1%
Holder tenure
17.2
Price vs estimated holder cost
-21.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.1%

Short interest

3 metrics
Short interest
4.3%
Latest settlement · 3.2 days to cover
Days to cover
3.2d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1628808 CUSIP 74319B502 13F (30d) 21 filings 20 filers Visit website Investor relations